ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ALPN Alpine Immune Sciences Inc

64.60
0.00 (0.00%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Alpine Immune Sciences Inc ALPN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 64.60 16:07:05
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
64.62 64.58 64.68 64.60 64.60
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/4/202415:27PRNUSKuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to..
11/4/202406:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
10/4/202415:15BWAlpine Immune Sciences Shares Updated Clinical Data from..
10/4/202415:01BWVertex Enters Into Agreement to Acquire Alpine Immune..
01/4/202408:00BWAlpine Immune Sciences to Present Updated Clinical Data for..
21/3/202406:45BWAlpine Immune Sciences Presents New Translational Data on..
20/3/202415:30BWAlpine Immune Sciences to Participate in Upcoming H.C...
18/3/202415:05BWAlpine Immune Sciences Provides Corporate Update and Full..
07/3/202415:30BWAlpine Immune Sciences to Report Fourth Quarter and Full..
26/2/202415:30BWAlpine Immune Sciences to Participate in Two Upcoming..
14/2/202415:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202408:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:12EDGAR2Form 8-K - Current report
01/2/202415:30BWAlpine Immune Sciences to Participate in Two Upcoming..
22/1/202417:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202417:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202417:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:45EDGAR2Form 8-K - Current report
04/1/202418:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202418:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202315:23EDGAR2Form 8-K - Current report
21/12/202315:15BWAlpine Immune Sciences Announces Amendment of Acazicolcept..
18/12/202315:30BWAlpine Immune Sciences to Present at the 42nd Annual J.P...
22/11/202309:25EDGAR2Form SC 13D/A - General statement of acquisition of..
20/11/202315:30BWAlpine Immune Sciences to Participate in the Evercore ISI..
15/11/202308:00BWAlpine Immune Sciences Presents New Translational Data on..
14/11/202315:15BWAlpine Immune Sciences Reports Third Quarter 2023 Financial..
13/11/202308:00BWAlpine Immune Sciences Presents New Translational Data on..
06/11/202320:41BWAlpine Immune Sciences Announces Pricing of $150 Million..
06/11/202320:37EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06/11/202305:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/11/202305:02EDGAR2Form 8-K - Current report
06/11/202305:00BWAlpine Immune Sciences Announces Proposed Public Offering
03/11/202308:00BWAlpine Immune Sciences Presents New Preclinical Data on..
02/11/202308:12EDGAR2Form 8-K - Current report
02/11/202308:00BWAlpine Immune Sciences Presents Initial Clinical Data on..
30/10/202308:00BWAlpine Immune Sciences to Present New Translational Data on..
13/10/202308:05BWAlpine Immune Sciences to Present Initial Clinical Data on..
04/10/202316:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202316:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/10/202307:00BWAlpine Immune Sciences Announces Appointment of Wolfgang..
12/9/202307:30BWAlpine Immune Sciences Presents First Preclinical Data for..
05/9/202315:30BWAlpine Immune Sciences to Participate in Two Upcoming..
05/9/202307:30BWAlpine Immune Sciences to Present First Preclinical Data for..
30/8/202315:30BWAlpine Immune Sciences Announces Initiation of Dosing in 240..
22/8/202315:30BWAlpine Immune Sciences Announces Appointment of M. Christina..
16/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
14/8/202315:26EDGAR2Form POS AM - Post-Effective amendments for registration..
14/8/202315:22EDGAR2Form 8-K - Current report
14/8/202315:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

Delayed Upgrade Clock